{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:07:18Z","timestamp":1777514838587,"version":"3.51.4"},"reference-count":68,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T00:00:00Z","timestamp":1451260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:p>Psoriasis is a common inflammatory disease with significant comorbidities, whose management can be challenging given the variety of treatment options. It is critical for nurse practitioners, physician assistants, general practitioners, and dermatology trainees to have useful information about the treatment and monitoring of patients with psoriasis. Although certain aspects of care apply to all patients, each therapeutic agent has its own nuances in terms of assessments, dosing, and monitoring. The most appropriate treatment is based not only on disease severity but also on comorbid conditions and concomitant medications. These practitioners are vital in facilitating patient care by thorough understanding of systemic agents, selection criteria, dosing, and recommended monitoring. This article provides high-yield practical pearls on managing patients with moderate to severe psoriasis. It includes case-based discussions illustrating considerations for special populations, such as pregnant women, children, and patients with comorbidities (eg, human immunodeficiency virus infection, hepatitis C, hepatitis B, and history of malignancy).<\/jats:p>","DOI":"10.1177\/1203475415623508","type":"journal-article","created":{"date-parts":[[2015,12,28]],"date-time":"2015-12-28T22:24:10Z","timestamp":1451341450000},"page":"196-206","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Managing Patients With Psoriasis in the Busy Clinic"],"prefix":"10.1177","volume":"20","author":[{"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Colorado Denver, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshi","family":"Aldredge","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Portland Veterans Affairs Medical Center, Portland, OR, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S.","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Dermatology Institute and Skin Care Center, Santa Monica, CA, USA"},{"name":"Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,12,28]]},"reference":[{"key":"bibr1-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.11.013"},{"key":"bibr2-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.029"},{"key":"bibr3-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.1410"},{"key":"bibr4-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.05.017"},{"key":"bibr5-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.047"},{"key":"bibr6-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.03.023"},{"key":"bibr7-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.006"},{"key":"bibr8-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.040"},{"key":"bibr9-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"bibr10-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.08.026"},{"key":"bibr11-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.055"},{"key":"bibr12-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"bibr13-1203475415623508","first-page":"519","volume":"51","author":"Afifi T","year":"2005","journal-title":"Can Fam Physician"},{"key":"bibr14-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.370"},{"key":"bibr15-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12276"},{"key":"bibr16-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5264"},{"key":"bibr17-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.018"},{"key":"bibr18-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13150"},{"key":"bibr19-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109997"},{"key":"bibr20-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109017"},{"key":"bibr21-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x"},{"key":"bibr22-1203475415623508","unstructured":"A study to evaluate the efficacy and safety of subcutaneous MK-3222, followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis (MK-3222-010) (NCT01722331). Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01722331. Accessed October 27, 2014."},{"key":"bibr23-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.01.025"},{"key":"bibr24-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.01.676"},{"key":"bibr25-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"bibr26-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13348"},{"key":"bibr27-1203475415623508","unstructured":"Cosentyx (secukinumab) [full prescribing information]. Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2015."},{"key":"bibr28-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.027"},{"key":"bibr29-1203475415623508","unstructured":"Rheumatrex (methotrexate) [full prescribing information]. DAVA Pharmaceuticals, Inc, Fort Lee, NJ, 2010."},{"key":"bibr30-1203475415623508","unstructured":"Lexicomp. Drug information handbook: a clinically relevant resource for all healthcare professionals. 23rd ed. Hudson, OH: Lexi-Comp; 2014."},{"key":"bibr31-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bdj.4811972"},{"key":"bibr32-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02644.x"},{"key":"bibr33-1203475415623508","unstructured":"Neoral (cyclosporine) [full prescribing information]. Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2013."},{"key":"bibr34-1203475415623508","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2010.22.2.212"},{"key":"bibr35-1203475415623508","unstructured":"Soriatane (acitretin) [full prescribing information]. Stiefel Laboratories, Inc, Research Triangle Park, NC, 2014."},{"key":"bibr36-1203475415623508","unstructured":"Otezla (ampremilast) [full prescribing information]. Celgene Corporation, Summit, NJ, 2014."},{"key":"bibr37-1203475415623508","first-page":"1","volume":"20","author":"Gooderham M","year":"2015","journal-title":"Skin Therapy Lett"},{"key":"bibr38-1203475415623508","author":"Paul C","journal-title":"Br J Dermatol"},{"key":"bibr39-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"bibr40-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.003"},{"key":"bibr41-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7304"},{"key":"bibr42-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1177\/120347540200600608"},{"key":"bibr43-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.271"},{"key":"bibr44-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.03.018"},{"key":"bibr45-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel400"},{"key":"bibr46-1203475415623508","first-page":"1014","volume":"33","author":"Carter JD","year":"2006","journal-title":"J Rheumatol"},{"key":"bibr47-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2013.11.004"},{"key":"bibr48-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30186.x"},{"key":"bibr49-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20250"},{"key":"bibr50-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.263"},{"key":"bibr51-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2008.00773.x"},{"key":"bibr52-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2010.03.006"},{"key":"bibr53-1203475415623508","first-page":"975","volume":"9","author":"Marji JS","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"bibr54-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.04.004"},{"key":"bibr55-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706290"},{"key":"bibr56-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.046"},{"key":"bibr57-1203475415623508","unstructured":"Humira (adalimumab) [full prescribing information]. AbbVie Inc, North Chicago, IL, 2014."},{"key":"bibr58-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker190"},{"key":"bibr59-1203475415623508","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i12.1531"},{"key":"bibr60-1203475415623508","first-page":"645","volume":"164","author":"Prignano F","year":"2011","journal-title":"Br J Dermatol"},{"key":"bibr61-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1149-4"},{"key":"bibr62-1203475415623508","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5070\/D37J65W53T","volume":"17","author":"Persad P","year":"2011","journal-title":"Dermatol Online J"},{"key":"bibr63-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.02973.x"},{"key":"bibr64-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1186\/ar2904"},{"key":"bibr65-1203475415623508","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20129"},{"key":"bibr66-1203475415623508","unstructured":"Enbrel (etanercept) [full prescribing information]. Immunex Corporation, Thousand Oaks, CA, 2013."},{"key":"bibr67-1203475415623508","unstructured":"Remicade (infliximab) [full prescribing information]. Janssen Biotech, Inc, Horsham, PA, 2013."},{"key":"bibr68-1203475415623508","unstructured":"Stelara (ustekinumab) [full prescribing information]. Janssen Biotech, Inc, Horsham, PA, 2013."}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475415623508","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1203475415623508","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475415623508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:53:23Z","timestamp":1777391603000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1203475415623508"}},"subtitle":["Practical Tips for Health Care Practitioners"],"short-title":[],"issued":{"date-parts":[[2015,12,28]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1177\/1203475415623508"],"URL":"https:\/\/doi.org\/10.1177\/1203475415623508","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,28]]}}}